Stanford Radiology to Advance Access to Astatine-211 Through New Collaboration with Atley Solutions and Telix Pharmaceuticals
Stanford Radiology is entering into a new international academic–industry collaboration with Atley Solutions and Telix Pharmaceuticals to establish the first operational supply chain for astatine-211 (At-211) in California. This initiative is designed to expand research access to this emerging theranostic isotope and support future clinical translation at Stanford and across the region.
Astatine-211 is an alpha-emitting radionuclide with demonstrated potential for targeted radionuclide therapy, particularly in the treatment of metastatic disease. While interest in At-211-based therapies continues to increase, the lack of reliable access in the western United States has limited advancements in translational research and early-phase clinical studies. This collaboration aims to overcome that limitation by establishing local infrastructure that supports consistent, high-quality production and use of At-211 radiopharmaceuticals.
This project brings together complementary expertise across academia and industry. The Cyclotron and Radiochemistry Facility (CRF) within the Stanford Medicine Department of Radiology will be providing a world-class environment that includes cGMP manufacturing capabilities, leading expertise in nuclear medicine and theranostics, and close integration with Stanford Medicine’s clinical and research programs. Atley Solutions will be contributing specialized technology with their At-211 solid target, isotope purification, and radiopharmaceutical synthesis, while Telix Pharmaceuticals will provide clinical development and commercialization experience in radiopharmaceuticals.
“Our cGMP facility and dedicated staff are ideally suited for advancing radiopharmaceutical development, and direct access to this theranostic isotope allows us to provide new treatment opportunities to our patients at Stanford Medicine,” said Gunilla Jacobson, PhD, Technical and Strategic Director, CRF. “This project solves a critical challenge in the isotope supply chain and opens the door for groundbreaking research as well as future clinical studies with At-211.”
At-211 will primarily be produced through irradiation of Atley’s bismuth-209 targets at the cyclotron located at the Crocker Nuclear Laboratory at the University of California, Davis, utilizing their higher energy beam required for astatine-211 production.
The CRF at Stanford Radiology, which operates two on-site cyclotrons, will focus on downstream isotope purification, radiochemistry, and translational activities. As part of the collaboration, an Atley C100 module will be installed at Stanford, enabling validation of the complete At-211 radiopharmaceutical workflow, from target processing through manufacture of the final drug product. The CRF will be producing the first At-211-labeled compound for clinical studies at Stanford Medicine later this year.
The project will run through 2026 and is supported by grant funding from VINNOVA through its 2025 “Deepened collaboration with USA, UK and Singapore within Health and Life Science” program. In addition to strengthening international collaboration, the initiative advances Stanford Radiology’s efforts to build sustainable avenues for translating novel radiopharmaceuticals from the laboratory to the clinic.
CRF staff Gurucharan Singh and Palak Kaur at work in the 1701 Page Mill site of the Cyclotron and Radiochemistry Facility.